R Barst

Summary

Publications

  1. doi request reprint How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
    R Barst
    Department of Pediatric Cardiology, Columbia University Medical Center, Scarsdale, NY 10583, USA
    Int J Clin Pract Suppl . 2010
  2. doi request reprint A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension
    Robyn J Barst
    Columbia University, New York, NY, USA
    Circulation 125:324-34. 2012
  3. pmc Updated evidence-based treatment algorithm in pulmonary arterial hypertension
    Robyn J Barst
    Columbia University, New York, New York 10583, USA
    J Am Coll Cardiol 54:S78-84. 2009
  4. pmc Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies
    Robyn J Barst
    Department of Pediatric Cardiology, Columbia University, New York, NY, USA
    Br J Haematol 149:426-35. 2010
  5. doi request reprint Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension
    Robyn J Barst
    Department of Pediatrics and Medicine, Columbia University, New York, New York, USA
    J Heart Lung Transplant 30:632-43. 2011
  6. pmc Pulmonary arterial hypertension: a comparison between children and adults
    R J Barst
    Division of Paediatric Cardiology, Columbia University College of Physicians and Surgeons, 31 Murray Hill Road, Scarsdale, New York, NY 10583, USA
    Eur Respir J 37:665-77. 2011
  7. doi request reprint Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management
    Robyn J Barst
    Columbia University College of Physicians and Surgeons, New York, NY, USA
    Circulation 125:113-22. 2012
  8. ncbi request reprint Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension
    D Wax
    Division of Pediatric Cardiology, Columbia University College of Physicians and Surgeons, New York, NY
    Chest 116:914-20. 1999
  9. ncbi request reprint Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
    R J Barst
    Columbia University College of Physicians and Surgeons, 3959 Broadway, BHN 2 255, New York, NY 10032, USA
    Eur Respir J 28:1195-203. 2006
  10. ncbi request reprint Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
    E B Rosenzweig
    Division of Pediatric Cardiology, Columbia Presbyterian Medical Center, New York, NY, USA
    Circulation 99:1858-65. 1999

Detail Information

Publications17

  1. doi request reprint How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
    R Barst
    Department of Pediatric Cardiology, Columbia University Medical Center, Scarsdale, NY 10583, USA
    Int J Clin Pract Suppl . 2010
    ..Prior to 1995, there were no approved therapies for PAH...
  2. doi request reprint A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension
    Robyn J Barst
    Columbia University, New York, NY, USA
    Circulation 125:324-34. 2012
    ..Safe, effective therapy is needed for pediatric pulmonary arterial hypertension...
  3. pmc Updated evidence-based treatment algorithm in pulmonary arterial hypertension
    Robyn J Barst
    Columbia University, New York, New York 10583, USA
    J Am Coll Cardiol 54:S78-84. 2009
    ..Atrial septostomy and lung transplantation are indicated for refractory patients or where medical treatment is unavailable...
  4. pmc Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies
    Robyn J Barst
    Department of Pediatric Cardiology, Columbia University, New York, NY, USA
    Br J Haematol 149:426-35. 2010
    ..Limited data in SCD-PH suggest that a low 6MWD predicts a low CO. Standard-dose bosentan appears to be well tolerated. Further investigation is warranted. Clinicaltrials.gov registration numbers NCT00310830, NCT00313196, NCT00360087...
  5. doi request reprint Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension
    Robyn J Barst
    Department of Pediatrics and Medicine, Columbia University, New York, New York, USA
    J Heart Lung Transplant 30:632-43. 2011
    ..Inclusion criteria included the option for background bosentan. Analyses of tadalafil in treatment-naive patients and as add-on to bosentan were pre-specified. Objectives were to provide safety and efficacy data for both groups...
  6. pmc Pulmonary arterial hypertension: a comparison between children and adults
    R J Barst
    Division of Paediatric Cardiology, Columbia University College of Physicians and Surgeons, 31 Murray Hill Road, Scarsdale, New York, NY 10583, USA
    Eur Respir J 37:665-77. 2011
    ....
  7. doi request reprint Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management
    Robyn J Barst
    Columbia University College of Physicians and Surgeons, New York, NY, USA
    Circulation 125:113-22. 2012
    ..Pulmonary arterial hypertension (PAH) is a rare but important cause of morbidity and mortality in children...
  8. ncbi request reprint Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension
    D Wax
    Division of Pediatric Cardiology, Columbia University College of Physicians and Surgeons, New York, NY
    Chest 116:914-20. 1999
    ..To determine whether long-term IV prostacyclin (PGI(2)) use improves exercise capacity in patients with primary pulmonary hypertension (PPH)...
  9. ncbi request reprint Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
    R J Barst
    Columbia University College of Physicians and Surgeons, 3959 Broadway, BHN 2 255, New York, NY 10032, USA
    Eur Respir J 28:1195-203. 2006
    ..In contrast, predicted survival was 69-38% over 1-4 yrs. The safety profile for long-term subcutaneous treprostinil was consistent with previous short-term trials with no unexpected adverse events...
  10. ncbi request reprint Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
    E B Rosenzweig
    Division of Pediatric Cardiology, Columbia Presbyterian Medical Center, New York, NY, USA
    Circulation 99:1858-65. 1999
    ....
  11. ncbi request reprint BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease
    K E Roberts
    Dept of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Eur Respir J 24:371-4. 2004
    ..The small number of patients studied and the ascertainment bias inherent in selecting for pulmonary arterial hypertension require further investigation...
  12. pmc Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure
    R J Barst
    Columbia University College of Physicians and Surgeons, New York, New York, USA
    Heart 90:e42. 2004
    ....
  13. ncbi request reprint Pulmonary arterial hypertension in children
    A Widlitz
    Dept of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Eur Respir J 21:155-76. 2003
    ....
  14. ncbi request reprint Medical therapy of pulmonary hypertension. An overview of treatment and goals
    R J Barst
    Department of Pediatrics, Columbia University College of Physicians and Surgeons, Division of Pediatric Cardiology, Pulmonary Hypertension Center, New York Presbyterian Hospital, New York, New York, USA
    Clin Chest Med 22:509-15, ix. 2001
    ..A brief overview of the pathology and pathobiology is presented as background for an introduction to the current medical therapy for pulmonary arterial hypertension as well as the goals for future treatment...
  15. ncbi request reprint Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension
    E Berman Rosenzweig
    New York Presbyterian Hospital, Division of Pediatric Cardiology, 3959 Broadway, Babies and Children s Hospital of New York, New York, NY 10032, USA
    Expert Opin Investig Drugs 10:811-23. 2001
    ..A comprehensive review of the newer agents, with an emphasis on the pathobiology/pathophysiology of pulmonary arterial hypertension provides insight into future management of paediatric pulmonary arterial hypertension...
  16. pmc Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene
    Z Deng
    Department of Psychiatry, College of Physicians and Surgeons at Columbia University and the New York State Psychiatric Institute, New York, NY, USA
    Am J Hum Genet 67:737-44. 2000
    ..These findings indicate that the bone morphogenetic protein-signaling pathway is defective in patients with primary pulmonary hypertension and may implicate the pathway in the nonfamilial forms of the disease...
  17. ncbi request reprint Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32
    J H Morse
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Circulation 95:2603-6. 1997
    ..The pathogenesis of primary pulmonary hypertension (PPH) is unknown, although in some instances families with multiple affected members suggest a genetic etiology...